New collaborative research led by Roswell Park shows that treatment with immune checkpoint inhibitors (ICIs) has led to a significant improvement in survival and response rates among patients with a particularly aggressive type of kidney cancer: advanced sarcomatoid renal cell carcinoma. The study is detailed in a presentation at the ASCO 2021 virtual annual meeting.

New work from a team at Roswell Park will help guide the care of patients with neuroendocrine tumors, or NETs. Abhay Singh, MD, MPH, and colleagues have discovered a potential biomarker to predict which patients are likely to experience side effects from a new targeted radiation treatment, peptide receptor radionuclide therapy (PRRT).